Avid Bioservices, Inc.
NASDAQ Capital Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Nicholas Stewart Green B.Sc., MBA
- Full Time Employees
- 371
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2642 Michelle Drive Tustin CA United States of America 92780
- IPO Date
- Apr 4, 1994
- CIK
- 0000704562
- Website
- avidbio.com
- Similar Companies
- Business
- Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Company News
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
Avid Bioservices, Inc. (CDMO) Q1 2025 Earnings Call Transcript
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
Lifecore Biomedical Announces Chief Financial Officer Transition
Avid Bioservices, Inc. (CDMO) Q4 2024 Earnings Call Transcript
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
EUROAPI and Priothera enter into CDMO collaboration to advance oncology project
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
Avid Bioservices: A Unique Growth Story With Many Tailwinds And Catalysts
Avid Bioservices to Participate at Upcoming Investor Conferences
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
Avid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call Transcript
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO